Canada
Public Health Agency of Canada
myocarditis, pericarditis, adverse events following immunization, mRNA vaccines, mRNA 1273, BNT162b2, COVID-19
Vaccine safety surveillance, Thrombosis with thrombocytopenia syndrome (TTS), adverse events following immunization, adenovirus vector COVID-19 vaccines, observed versus expected analysis, ChAdOx1-S [recombinant], Ad26.COV2.S